GRAND RAPIDS, Mich. , March 25, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients suffering with diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced that its executives will be speaking at the following upcoming healthcare conferences: MedInvest Biotech & Pharma Investor Conference 1 in New York, NY on Friday, March 28 .
2:20 PM ET : Phase 2b -proven Clinical Candidate 0602K Under Development for Obesity/Overweight, T2D & MASH CEO Robert Beardsley , Ph.D., will discuss the key role of insulin resistance and opportunities in metabolic disease for 0602K .
GLP-1 -Based Therapeutics Summit 2 in Boston, MA , on Wednesday, April 30 . 9:00 AM ET : New Insulin Sensitizers as a Golden Combination With GLP-1 & Weight Loss Therapies CSO Jerry Colca, Ph.D.
, will discuss how reprogramming mitochondria by targeting the mitochondrial pyruvate carrier (MPC) with Cirius' 0602K drives metabolic changes that synergize with GLP-1 receptor agonists to improve treatment effects, including preventing the loss of skeletal muscle. Combination treatment may improve weight loss durability and patient health outcomes. 5:00 PM ET : Subcutaneous Vs Oral Administration in GLP-1 : Will Oral Administration Really Improve Patient Adherence? Dr.
Colca will also participate in a panel discussing the role of oral GLP-1 therapies to improve patient adherence across the spectrum of chronic metabolic disease and fa.
